Effect of acute hyperinsulinaemia with and without angiotensin II type 1 receptor blockade on resistin and adiponectin concentrations and expressions in healthy subjects.
OBJECTIVE
The potential insulin-sensitizing function of angiotensin II type 1 receptor blockade (ARB) with regard to selected adipokines is not fully explained so far. Our study aimed to explore the influence of acute hyperinsulinaemia and acutely induced ARB on resistin and adiponectin concentrations and expressions in healthy subjects.


METHODS
Plasma adipokines were measured: 1) at 0, 30 and 240 min of hyperinsulinaemic (1 mU/kg per min) euglycaemic (5 mmol/l) clamp (HEC), and 2) during HEC after acute ARB (losartan 200 mg; AT-HEC) using the same protocol, in eight healthy subjects. Needle biopsy of abdominal s.c. fat was performed at 0, 30 and 240 min of both clamps to assess the adipokines' expressions.


RESULTS
Comparing the glucose disposals of HEC and AT-HEC, no difference in insulin sensitivity was found. Plasma resistin increased equally during HEC and AT-HEC (P < 0.05). The expression of resistin in s.c. fat increased during HEC (P < 0.05), while no significant changes in expression were observed during AT-HEC. Plasma levels of adiponectin did not change during both clamps. Adiponectin expression increased during HEC (P < 0.05), while it did not change during AT-HEC.


CONCLUSIONS
In healthy subjects, acute hyperinsulinaemia is associated with an increase in plasma resistin independently of ARB, while plasma adiponectin is not influenced by insulin or ARB. The expressions of both resistin and adiponectin in s.c. adipose tissue are stimulated by acute hyperinsulinaemia, whereas losartan attenuates their insulin-stimulated expressions. This suggests a potential effect of losartanon adipokines' expression.
Krusinová
E
E
Institute for Clinical and Experimental Medicine, Diabetes Centre, Vídenská 1958/9, 140 21 Prague, Czech Republic.
Klementová
M
M
Kopecký
J
J
Wohl
P
P
Kazdová
L
L
Mlejnek
P
P
Pravenec
M
M
Hill
M
M
Pelikánová
T
T
D052242:Adiponectin / Q000097:blood / Q000235:genetics / Q000378:metabolism; D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage; D004338:Drug Combinations; D015870:Gene Expression / Q000187:drug effects; D015309:Glucose Clamp Technique; D006262:Health; D006801:Humans; D006946:Hyperinsulinism / Q000139:chemically induced*; D007328:Insulin / Q000008:administration & dosage*; D050152:Intra-Abdominal Fat / Q000187:drug effects / Q000378:metabolism; D019808:Losartan / Q000008:administration & dosage*; D008297:Male; D044140:Receptor, Angiotensin, Type 1 / Q000502:physiology; D052243:Resistin / Q000097:blood* / Q000235:genetics* / Q000378:metabolism
C499918:ADIPOQ protein, human; D052242:Adiponectin; D047228:Angiotensin II Type 1 Receptor Blockers; D004338:Drug Combinations; D007328:Insulin; C499624:RETN protein, human; D044140:Receptor, Angiotensin, Type 1; D052243:Resistin; D019808:Losartan